Nov 14, 2006|
Pharma: Domestic over MNC...
If the results over the last few quarters are anything to go by, the domestic pharma companies have performed better than their MNC counterparts. This has also been reflected in the stock prices, which have seen domestic pharma stocks garner stronger investor interest as compared to MNC stocks. However, the scenario was the opposite a year back when relatively poor results announced by domestic pharma companies prompted investors to flock to MNC stocks, which had the 'more stable' tag attached to them. So what has happened in the past one year for the shift in preference? Let us understand.
Domestic companies: Domestic pharma companies have performed well over the last few quarters mainly due to increase in revenues from the highly competitive US market, strong sales in the domestic market and contribution from acquisitions. In the US market, these companies, despite increasing competition and price erosion, have been able to deliver better results due to benefits from 180-day exclusivities received for certain products. For instance, Ranbaxy and Dr. Reddy's (as authorised generic) have benefited from 'Zocor', Cipla from 'Proscar' and 'Zoloft' (the company is the API supplier to Teva, who has received the exclusivity period for these drugs) and Sun Pharma from 'Ultracet'. Besides this, the acquisitions made by domestic companies either in the generics space or the custom manufacturing space have also started contributing to the overall performance.
Also, while the product patent law is likely to result in a slow down in new product launches in the long-term, the impact up till now has not been significant. Most of these companies have adopted the in-licensing route to bridge the product gap. In fact, barring issues such as VAT concerns in 4QFY05, which affected the entire Indian pharma industry, domestic companies have been posting strong growth rates in the Indian market.
MNC companies: New launches from the parents' product stable will be critical for MNC pharma companies going forward, as this is one factor that gives them an edge over their domestic counterparts. Besides this, MNC majors are looking at in-licensing products from other global companies given their strong reach in the domestic market. That said, barring Pfizer, which introduced 3 products at the start of the year, some of the other MNC companies have not yet made any significant launches. Launch of patented products in the country is unlikely to take place before late CY07 or CY08. Meanwhile, the existing products of the companies are driving the current growth in revenues.
MNC pharma stocks have been accorded higher valuations in comparison to domestic companies, as the former can rely on their parents' strong research pipeline to launch products in the country and also due to the fact that their revenue streams tend to be relatively more stable. It must be noted that these companies are domestic market-centric. On the other hand, domestic companies, despite increasing challenges in the global generics market, are focusing on widening their geographical reach to de-risk their revenue profile. Thus, while any adverse conditions in the domestic market will affect MNC companies more than their domestic peers, volatility in revenues in overseas markets will affect Indian companies to a larger extent.
Challenges abound for both domestic and MNC players going forward. Intense competition and price erosion (both due to competition and regulatory changes) in the global generics market and integrating acquisitions will test the mettle of domestic companies. Similarly, for MNC majors, launch of patented products may not be that easy chiefly in terms of pricing of these products. Given the fact that the government intends to make medicines affordable to the public, prices of patented products are most likely to be subject to negotiation.
Each business model has its pros and cons. Therefore, whether MNC or domestic, what is important is the ability of companies to innovate even in adverse conditions and consistency in performance over the years. And after considering all these factors, valuations are important and certainly cannot be ignored.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
Aug 16, 2017
And what it has in common with beating the stock market too.
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 14, 2017
Last week's correction is making a number of Super Investor stocks look a lot more attractive...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407